Vijay Kumar
Stock Analyst at Evercore ISI Group
(3.25)
# 1,052
Out of 5,156 analysts
289
Total ratings
49.15%
Success rate
1.04%
Average return
Main Sectors:
Stocks Rated by Vijay Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAI Caris Life Sciences | Maintains: Outperform | $38 → $34 | $19.00 | +78.95% | 3 | Feb 27, 2026 | |
| PEN Penumbra | Maintains: Outperform | $340 → $360 | $339.61 | +6.00% | 3 | Feb 26, 2026 | |
| USB U.S. Bancorp | Maintains: In-Line | $60 → $65 | $52.13 | +24.69% | 8 | Feb 5, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Outperform | $95 → $98 | $75.63 | +29.58% | 6 | Feb 5, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $112 → $96 | $71.90 | +33.52% | 8 | Feb 5, 2026 | |
| AZTA Azenta | Maintains: Outperform | $50 → $45 | $23.13 | +94.55% | 10 | Feb 5, 2026 | |
| TWST Twist Bioscience | Maintains: Outperform | $42 → $52 | $48.33 | +7.59% | 7 | Feb 3, 2026 | |
| RVTY Revvity | Maintains: Outperform | $112 → $118 | $92.11 | +28.11% | 4 | Feb 3, 2026 | |
| ISRG Intuitive Surgical | Maintains: In-Line | $580 → $550 | $493.56 | +11.44% | 15 | Jan 23, 2026 | |
| ABT Abbott Laboratories | Maintains: Outperform | $144 → $138 | $112.65 | +22.50% | 18 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $168 → $223 | $217.46 | +2.55% | 9 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $79 → $78 | $75.59 | +3.19% | 17 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $105 | $103.71 | +1.24% | 8 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $18 | $17.22 | +4.53% | 12 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $14 → $12 | $8.15 | +47.24% | 13 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $94 → $120 | $93.28 | +28.64% | 15 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $194 → $210 | $123.75 | +69.70% | 3 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $155 → $160 | $116.64 | +37.17% | 8 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $405 | $365.92 | +10.68% | 13 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $142 | $124.28 | +14.26% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $88 → $92 | $84.26 | +9.19% | 15 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $525 → $590 | $509.97 | +15.69% | 13 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,275 → $1,400 | $1,248.62 | +12.12% | 12 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $226 → $245 | $198.80 | +23.24% | 4 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $31 | $17.91 | +73.09% | 8 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $103 → $106 | $91.34 | +16.05% | 5 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $46 | $24.66 | +86.54% | 4 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $3 | $3.20 | -6.25% | 6 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $18 → $30 | $12.91 | +132.38% | 11 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $335 → $355 | $305.67 | +16.14% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $160 | $87.69 | +82.46% | 7 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $286 → $290 | $165.46 | +75.27% | 6 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.16 | +503.45% | 1 | May 31, 2022 |
Caris Life Sciences
Feb 27, 2026
Maintains: Outperform
Price Target: $38 → $34
Current: $19.00
Upside: +78.95%
Penumbra
Feb 26, 2026
Maintains: Outperform
Price Target: $340 → $360
Current: $339.61
Upside: +6.00%
U.S. Bancorp
Feb 5, 2026
Maintains: In-Line
Price Target: $60 → $65
Current: $52.13
Upside: +24.69%
GE HealthCare Technologies
Feb 5, 2026
Maintains: Outperform
Price Target: $95 → $98
Current: $75.63
Upside: +29.58%
Boston Scientific
Feb 5, 2026
Maintains: Outperform
Price Target: $112 → $96
Current: $71.90
Upside: +33.52%
Azenta
Feb 5, 2026
Maintains: Outperform
Price Target: $50 → $45
Current: $23.13
Upside: +94.55%
Twist Bioscience
Feb 3, 2026
Maintains: Outperform
Price Target: $42 → $52
Current: $48.33
Upside: +7.59%
Revvity
Feb 3, 2026
Maintains: Outperform
Price Target: $112 → $118
Current: $92.11
Upside: +28.11%
Intuitive Surgical
Jan 23, 2026
Maintains: In-Line
Price Target: $580 → $550
Current: $493.56
Upside: +11.44%
Abbott Laboratories
Jan 23, 2026
Maintains: Outperform
Price Target: $144 → $138
Current: $112.65
Upside: +22.50%
Jan 13, 2026
Maintains: Outperform
Price Target: $168 → $223
Current: $217.46
Upside: +2.55%
Jan 5, 2026
Downgrades: In-Line
Price Target: $79 → $78
Current: $75.59
Upside: +3.19%
Jan 5, 2026
Downgrades: In-Line
Price Target: $105
Current: $103.71
Upside: +1.24%
Jan 5, 2026
Downgrades: In-Line
Price Target: $18
Current: $17.22
Upside: +4.53%
Jan 5, 2026
Downgrades: In-Line
Price Target: $14 → $12
Current: $8.15
Upside: +47.24%
Jan 5, 2026
Upgrades: Outperform
Price Target: $94 → $120
Current: $93.28
Upside: +28.64%
Jan 5, 2026
Upgrades: Outperform
Price Target: $194 → $210
Current: $123.75
Upside: +69.70%
Jan 5, 2026
Upgrades: Outperform
Price Target: $155 → $160
Current: $116.64
Upside: +37.17%
Oct 31, 2025
Maintains: Outperform
Price Target: $410 → $405
Current: $365.92
Upside: +10.68%
Oct 31, 2025
Maintains: Outperform
Price Target: $132 → $142
Current: $124.28
Upside: +14.26%
Oct 31, 2025
Maintains: Outperform
Price Target: $88 → $92
Current: $84.26
Upside: +9.19%
Oct 7, 2025
Maintains: Outperform
Price Target: $525 → $590
Current: $509.97
Upside: +15.69%
Oct 7, 2025
Maintains: Outperform
Price Target: $1,275 → $1,400
Current: $1,248.62
Upside: +12.12%
Oct 7, 2025
Maintains: Outperform
Price Target: $226 → $245
Current: $198.80
Upside: +23.24%
Oct 7, 2025
Maintains: Outperform
Price Target: $33 → $31
Current: $17.91
Upside: +73.09%
Jul 8, 2025
Maintains: Outperform
Price Target: $103 → $106
Current: $91.34
Upside: +16.05%
Jul 8, 2025
Maintains: Outperform
Price Target: $48 → $46
Current: $24.66
Upside: +86.54%
May 19, 2025
Maintains: In-Line
Price Target: $3
Current: $3.20
Upside: -6.25%
Dec 2, 2024
Upgrades: Outperform
Price Target: $18 → $30
Current: $12.91
Upside: +132.38%
Oct 1, 2024
Maintains: In-Line
Price Target: $335 → $355
Current: $305.67
Upside: +16.14%
Oct 1, 2024
Maintains: Outperform
Price Target: $120 → $160
Current: $87.69
Upside: +82.46%
Oct 1, 2024
Maintains: Outperform
Price Target: $286 → $290
Current: $165.46
Upside: +75.27%
May 31, 2022
Initiates: Outperform
Price Target: $7
Current: $1.16
Upside: +503.45%